Replies to post #322 on ArQule Inc. (ARQL)

[NSX]

$ARQL.....in apparent response to a just-released abstract on blood cancer candidate ARQ 531, a reversible BTK inhibitor, that will be presented at ASH next month.

https://ash.confex.com/ash/2019/webprogram/Paper127260.html

I believe people are comparing this BTK inhibitor Phase ! dosing and safety to Lilly more favorable safety profile

There is more there......for example a lower dose of 65 mg is now being tested and safer...more to follow